Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C. Byrd, Wojciech Jurczak, Susan O’Brien et al.|Journal of Clinical Oncology|2021Cited by 630
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R. Mato, Colleen Dorsey, Lindsey E. Roeker et al.|Clinical Cancer Research|2020Cited by 115
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignanciesJohn N. Allan, Jennifer R. Brown, Javier Pinilla‐Ibarz et al.|Haematologica|2021Cited by 37